ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology

Arends, Jann; Bodoky, G.; Bozzetti, Federico; Fearon, Kenneth C. H.; Muscaritoli, Maurizio; Selga, Guntars; Schueren, Marian A.E. de van der; Meyenfeldt, M.F. von; Zürcher, G.; Fietkau, Rainer; Aulbert, E.; Frick, Barbara; Holm, Matilda; Kneba, Michael; Mestrom, H. J.; Zander, Axel R.

doi:10.1016/j.clnu.2006.01.020

Cited by 649 publications

(440 citation statements)

References 118 publications

Supporting

Mentioning

369

Contrasting

Unclassified

Order By: Relevance

“…In 2006, the European Society for Clinical Nutrition and Metabolism (ESPEN) did not recommend EN and preferred PN in SCT patients because of no proven effects upon the tumour response to treatment, therapy-associated side effects, graft survival, aGVHD and overall survival. 9 In 2009, despite successful use of EN, the ESPEN recommended that PN should be reserved for SCT patients with severe mucositis, ileus or intractable vomiting. 5 That same year, a Cochrane review confirmed PN as the first choice in preventing malnutrition in these patients despite a recognised increased risk of infection, and presented EN as an alternative in the absence of data necessary to properly compare PN with EN.…”

Section: Discussionmentioning

confidence: 99%

Enteral nutrition: a first option for nutritional support of children following allo-SCT?

Azarnoush

Bruno

Béghin

et al. 2012

Bone Marrow Transplant

View full text Add to dashboard Cite

Parenteral nutrition (PN) is the treatment of choice for nutritional support of patients undergoing allo-SCT following myeloablative conditioning (MAC). Here we prospectively assessed the outcomes of early enteral nutrition (EN) in a paediatric cohort. From 2003 to 2010, all 65 consecutive children undergoing MAC allo-SCT at our referral centre began EN the day after transplantation. Post-transplant and nutritional outcomes of patients receiving only EN (EN group, n ¼ 50) were compared with those of patients requiring additional PN (EN-PN group, n ¼ 15). In the EN group time to platelet recovery (P ¼ 0.01) and length of hospitalisation (Po0.001) were shorter, while in the EN-PN group the proportion of unrelated donors (P ¼ 0.02) and the frequency of severe acute GVHD (aGVHD; P ¼ 0.004) were higher. All patients were alive at day 100. PN was started 14 days after transplant because of poor digestive tolerance to EN or severe gut aGVHD. The body mass index Z-score in the EN-PN group decreased from transplant to discharge (P ¼ 0.02). In only 23% of cases was PN required for severely ill patients. Our results suggest that EN might be considered to be an option for nutritional support in children undergoing MAC allo-SCT, while PN should be used only as a rescue option, possibly in combination with EN.

show abstract

Section: Discussionmentioning

confidence: 99%

Enteral nutrition: a first option for nutritional support of children following allo-SCT?

Azarnoush

Bruno

Béghin

et al. 2012

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…Taken together, these data provide a rationale for the use of strategies to limit and treat weight loss as part of care for people with cancer and indeed nutritional management is a widely accepted strategy recommended by a number of bodies (7)(8)(9) .…”

mentioning

confidence: 95%

The effectiveness of nutritional interventions in malnutrition and cachexia

Baldwin

2015

Proc. Nutr. Soc.

View full text Add to dashboard Cite

Conference on 'Nutrition and age-related muscle loss, sarcopenia and cachexia' Symposium 3: Nutrition for prevention and interventions for sarcopenia and cachexiaThe effectiveness of nutritional interventions in malnutrition and cachexia There are similarities and differences between definitions of both malnutrition and cachexia and studies of oral nutritional interventions have failed to use standard criteria at study inclusion contributing to heterogeneity amongst studies. Meta-analysis of randomised controlled trials has suggested limited evidence of benefit to nutritional and clinical outcomes but some improvements to aspects of quality of life. The presence of cachexia in patients with cancer might explain the limited efficacy of simple oral nutritional interventions, which lack a component designed to address metabolic abnormalities associated with cachexia. Novel strategies combining nutritional support with therapeutic agents designed to down-regulate the metabolic aberrations have failed to demonstrate consistent benefits and the results of multimodal treatments combining several interventions are awaited. There is a need for intervention studies recruiting patients early in the disease course, which underlines the need for definitions which predict poor outcome and hence allow early recognition of vulnerable patients. Christine Baldwin Malnutrition: Cachexia: Oral nutritional support: Systematic review: Meta-analysisThe most recent data indicate that worldwide there were about 14 million new cases of cancer diagnosed in 2012 and greater than 330 000 diagnoses being made in the UK in 2011 (1,2) . Cancer remains a leading cause of death worldwide and it is estimated that that 8·2 million people died from cancer in 2012 with about 162 000 deaths from cancer in the UK (1) . Despite the dismal nature of these data, more than half of people diagnosed with cancer will survive for 10 years or more; (1) therefore efforts to maximise the ability of patients to respond to treatment and to achieve a good quality of life are paramount. The morbidity experienced by people with cancer arises from the presence of disease and from the side-effects of treatment. The presence, number and intensity of symptoms are likely to account for a large amount of the suffering experienced by patients. Weight loss is a common symptom in people diagnosed with cancer. A pooled prevalence for any amount of weight loss of 46 (95 % CI 34, 59) % was reported by a systematic review of symptom prevalence in people with incurable cancer (3) . Amounts of weight loss vary according to the site and stage of disease. A retrospective review of 3047 patients with different cancers entering clinical trials, reported a prevalence varying from 31 % to 87 % with the greatest amounts of weight loss found in patients with cancers of the upper gastrointestinal tract (4) . In a group of patients with advanced

show abstract

“…Obviamente dado el reducido número de casos las diferencias no alcanzaron significación estadística. A pesar de las recomendaciones de la ASPEN y ESPEN 35 , esta práctica aún no se ha instituido de rutina, pero nuestros pocos casos sugieren que puede ser de utilidad, independiente del estado nutricional y estadío tumoral. Por lo tanto, queda como tarea a futuro verificar si el soporte preoperatorio puede determinar menores complicaciones postoperatorias.…”

Section: Discussionunclassified